ET-600 is under clinical development by Eton Pharmaceuticals and currently in Phase I for Diabetes Insipidus. According to GlobalData, Phase I drugs for Diabetes Insipidus does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ET-600 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ET-600 overview

ET-600 is under development for the treatment of diabetes insipidus.

Eton Pharmaceuticals overview

Eton Pharmaceuticals is a pharmaceutical company. It develops and commercializes pharmaceutical products including formulations. The company’s marketed products are Alkindi Sprinkle, Betaine Anhydrous, and Carglumic Acid. Its pipeline products include dehydrated alcohol injection, ZENEO hydrocortisone autoinjector, ET-400, and ET-500. Eton Pharmaceuticals develops its products in multiple dosage forms including liquid formulations, sterile injectables, oral liquids, and ophthalmics. The company leverages relationships with development partners in the US and Europe to create a portfolio of products. The company’s products find application in therapeutic areas including endocrinology and metabolic genetics. Eton Pharmaceuticals is headquartered in Deer Park, Illinois, the US.

For a complete picture of ET-600’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.